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Objectives This study sought to define the importance of 5-year coronary artery disease (CAD) progression after
successful stenting.
Background Safety concerns regarding first-generation drug-eluting stents mandate 5-year follow-up studies. However, only
limited data exist on the long-term importance of CAD progression relative to late stent–related problems.
Methods This study followed for 5 years, 428 consecutive patients randomized to drug-eluting versus bare-metal stents
with successful stenting documented by freedom from symptoms/events and no ischemic perfusion defects
(PDs) after 6 months. Rest/stress scintigraphic scans were repeated after 60 months. Late events and new PDs
in areas remote from stented vessels indicated CAD progression.
Results During follow-up, 110 of 428 (25.7%) patients had 150 clinical events: 43 patients (10%) died, 36 (8.4%) suf-
fered a myocardial infarction, and 71 (16.6%) needed repeat revascularization. Event rates were lower in remote
versus target-vessel areas (9.8% vs. 14.3%, p  0.019). Remote myocardial infarction and repeat revasculariza-
tion accounted for 46 of 124 (37.1%) nonfatal events and were similar for both stent types. Five-year scinti-
graphic studies in patients without follow-up events showed 23.3% new PDs, 71% of which were asymptomatic.
Remote defects accounted for 37.5% PDs and were similar for both stent types.
Conclusions Even 5 years after stenting, target-vessel events and/or new PDs remained more frequent than CAD progression
assessed by remote events and/or new PDs. Still, remote events accounted for almost 40% of all events with a
similar rate of additional new PDs, often silent, and independent of stent type. This documents the importance
of CAD progression and stresses the need to differentiate remote from target-vessel events/PDs in long-term
stent safety studies. (Basel Stent Kosten-Effektivitäts Trial [BASKET]; ISRCTN75663024) (J Am Coll Cardiol
2012;59:793–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.024Safety concerns regarding late cardiac death or nonfatal
myocardial infarction (MI) related to late stent thrombosis
mandate prolonged follow-up after implantation of first-
generation drug-eluting stents (DES) (1). Late stent throm-
boses occurring after 6 to 12 months after the intervention,
first observed in individual patients (2), were found to occur
more often after DES than after bare-metal stent (BMS) use
in the “all-comer” angioplasty population of the BASKET
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2011, accepted November 11, 2011.(Basel Stent Kosten-Effektivitäts Trial) (3). The rate was
low and did not affect overall mortality. This was confirmed
in several studies and registries (4,5) with rates of definite
stent thrombosis according to the Academic Research
Consortium’s definitions (6) after DES implantation of
approximately 0.6% per year, steadily increasing up to 4
See page 800
years of follow-up (7). Still, 5-year follow-up reports of the
pivotal DES trials (8,9) confirmed the benefits of first-
generation DES, compared with BMS, in reducing target-
vessel (TV) revascularization without increasing overall
death or MI rates.
In view of the progressive nature of coronary artery
disease (CAD), it could be expected that during prolonged
follow-up investigations after stenting, cardiac events would
occur irrespective of this procedure in vessels or locations
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In a low-risk clinical trial popu-
lation treated with BMS, hazard
rates for late non-TV events were
about 3 times higher than for TV
events (10). In long-term follow-up
investigations of pooled early
DES trials (11,12), events attrib-
uted to non-TVs were estimated
at 26% during years 2 to 5 after
the intervention, with similar
rates in DES- and BMS-treated
patients. However, these findings
were based on observations of
low-risk patients and influenced by protocol-driven repeat
coronary angiographies and limited follow-up rates. Impor-
tantly, in a broader population of patients including those
with multivessel disease, the importance of CAD progres-
sion can only be assessed if the initial revascularization is
shown to be successful and complete. In addition, disease
progression may not only manifest as death, remote MI, and
angina-driven non-TV revascularization, but also as symp-
tomatic or silent new perfusion defects (PDs).
Thus, the aim of the present prospective investigation was to
define the importance of CAD progression over a 5-year
period after successful complete revascularization by angio-
plasty and stenting in a comprehensive manner capturing
clinically symptomatic and silent disease and comparing it
between patients randomized to DES versus BMS. We hy-
pothesized that during late follow-up, clinical CAD progres-
sion could become as relevant as symptomatic late stent
problems occurring irrespective of stent type implanted.
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CAD  coronary artery
disease
DES  drug-eluting stent(s)
MI  myocardial infarction
PDs  perfusion defects
SPECT  single-photon
emission computed
tomography
TV  target vessel
Figure 1 Patient Flow Chart
The flow chart shows the derivation of the study population from 826 consecutive
BASKET  Basel Stent Kosten-Effektivitäts Trial; SPECT  single-photon emissionMethods
Patients and study design. BASKET included 826 con-
secutive patients treated with angioplasty and stenting
between May 2003 and May 2004 at the University
Hospital of Basel, Switzerland, excluding only those with
restenotic lesions, in need of 4-mm stents and those not
consenting (13). Patients presented with stable symptoms
in 42%, unstable angina in 36%, and with ST-segment
elevation MI in 21% of cases, whereas 69% had multi-
vessel CAD and 66% at least 1 “off-label” indication.
Patients were randomized 2:1 to DES or BMS.
Follow-up findings have been reported after 18 (3) and
36 months (14). In addition, all patients surviving the
initial 6 months were invited for a rest/stress myocardial
perfusion scintigraphy using single-photon emission
computed tomography (SPECT) (15).
This patient population and dataset provided a unique
opportunity for the present prospective outcome study, the
BASKET-PRO (BASKET-PROgression of CAD study).
Based on a new protocol with a new ethical approval and a
new written informed patient consent, all BASKET pa-
tients without clinical CAD manifestations up to 6 months
after the intervention, no ischemic perfusion defects at this
point in time, and surviving up to 5 years after stenting were
invited to undergo a further follow-up examination includ-
ing history, current therapy, clinical examination, electro-
cardiography as well as a second rest/stress myocardial
perfusion scintigraphy performed 5.5  0.25 years after
stent implantation. Follow-up was performed in the outpa-
tient clinic in all patients. The patient flow is detailed in
Figure 1.
ts for the clinical follow-up and the repeat scintigraphic studies.
uted tomography.patien
comp
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aim and analysis of BASKET-PRO was to assess the
magnitude of clinically relevant symptomatic and silent
CAD progression remote from the stented area based on
late events and perfusion findings (i.e., MI, revasculariza-
tion, and new PDs in remote versus revascularized regions
of the myocardium between 6 months and 5 years), irre-
spective of stent type. Secondary analyses evaluated the
outcome between subgroups of patients treated with DES
or BMS and 5-year mortality.
All events were adjudicated by a critical event committee
blinded to stent type. Cardiac death was defined as death
not clearly of extracardiac origin. Because death cannot be
assigned to any vessel segment, death was not counted as a
TV or remote event. Similarly, 2 MIs that could not be
located (pre-existing left bundle branch block, unspecific
electrocardiographic abnormalities) were not counted as
remote or TV events. Myocardial infarction was defined as
previously described (13) and attributed to myocardial
segments or coronary vessels based on angiography, if
available; scintigraphic findings; or serial electrocardio-
grams. In this study, repeat coronary angiography and
revascularization were only allowed if clinically indicated.
The TV was defined as the epicardial coronary artery or 1 of
its side branches originally stented. In multivessel disease, all
initially stented vessels were counted as target vessels.
Findings were labeled non-TV or “remote” if there was clear
evidence of non-TV involvement. In cases of multiple
occurrences of the same event, the time to the first event was
used as the time the event occurred. The period 7 months to
5 years was used to define progression of CAD. Patients
with remote events and/or remote new PDs during this late
period were assumed to have clinical CAD progression,
whereas those without events and normal perfusion scans or
no change since the first scintigraphy were not. In this
study, the initial 6 months after stenting were not consid-
ered for CAD progression because early clinical assessments
and scintigraphic studies for the present prospective inves-
tigation were performed at this point in time (15), which
has been defined as the end of the “restenotic phase” after
stenting (16).
Myocardial perfusion studies. SPECT studies were per-
formed following a standard protocol (15) as previously
described (17). In short, a rest-stress dual-isotope (201-
thallium/99m technetium sestamibi) protocol with exercise
or pharmacologic (adenosine) stress and electrocardio-
graphic monitoring was used after withdrawal of antianginal
drugs if possible. Images were scored using a 17-segment
model with a 5-point scale from 0  normal to 4  no
uptake. Summed stress and rest scores were calculated and
converted to percentage of myocardium affected and differ-
ence scores as measures of ischemia derived thereof. Perfu-
sion defects were correlated to TV or remote territories as
recommended by the American Heart Association (18) by
observers blinded to stent types used and vessels treated. A
defect score that affected 5% of the myocardium was sconsidered significant. Silent PDs were all significant re-
versible defects that were not associated with anginal chest
pain during the days and months prior to testing.
Statistics. All data are presented as mean  SD or pro-
portions. Categorical variables were compared using the
Fisher exact test or the McNemar test and the Student t test
for continuous variables as appropriate. A 2-sided p value
0.05 was considered statistically significant. Analyses were
performed using commercially available software (SSPS
19.0, SPSS, Inc., Chicago, Illinois).
Results
Baseline characteristics of the study population (n  428)
are summarized in Table 1 and compared with the remain-
ing 398 BASKET patients who were excluded here because
they either had clinical events up to 6 months, had a positive
or no 6-month SPECT study, or were lost to follow-up
(Fig. 1). These characteristics were remarkably similar for
both patient groups, the only significant difference being a
higher rate of multivessel disease in excluded patients
associated with early events as exclusion for this long-term
evaluation (Table 1).
Follow-up. Five-year follow-up regarding survival was
98% and complete follow-up was reached in 97% of cases
(Fig. 1). After 5 years, patients (age 69  11 years, 77%
men) were on the following relevant drug therapy: aspirin
76%, clopidogrel 21%, both 8%, statins 64%, beta-blocking
drugs 60%, calcium antagonists 15%, and long acting
nitrates 3%.
Figure 1 shows that 476 patients, 64% of all BASKET
patients, consented to a 6-month SPECT study and that
442 (93%) were free of symptoms, events, and ischemic
PDs. Of this potential study population, 14 (3%) were lost
to 5-year follow-up leaving 428 (97%) for the present
long-term clinical investigation. Because 110 of them had
Baseline Characteristics of thePresent Study Population Compared Withth Remaining (Exc uded) BASKET Pat ents
Table 1
B seline Charact ristics of the
Present Study Population Compared With
the Remaining (Excluded) BASKET Patients
Present Study
Population
(n  428)
Excluded BASKET
Population
(n  398)
p
Value
Age, yrs 63.7 11.2 64.0 11.4 0.70
Male 77 78 0.87
Diabetes 19 19 0.93
Hyperlipidemia 77 74 0.42
Hypertension) 67 65 0.71
Smoking 29 28 0.76
Stable angina 44 40 0.25
Unstable angina 37 36 0.77
STEMI 19 24 0.08
Multivessel disease 31 42 0.001
Number of stents 1.94 1.11 1.81 0.97 0.06
BMS 34 34 0.83
Values are mean  SD or %.
BASKET Basel Stent Kosten-Effektivitäts Trial; BMS  bare-metal stent(s); STEMI  ST-
egment elevation myocardial infarction.
796 Zellweger et al. JACC Vol. 59, No. 9, 2012
CAD Progression Late After Stent Implantation February 28, 2012:793–9late follow-up events, 318 were asked for a 5-year SPECT
study, of whom 206 (65%) consented. They form the basis
for the long-term scintigraphic analysis.
Long-term clinical events. During months 7 to 60, 110 of
428 patients (25.7%) had 150 clinical events: 43 (10%) died,
36 (8.4%) suffered an MI, and 71 (16.6%) needed revascu-
larizations for new symptoms (Table 2). Nineteen clinical
events pertained at the same time to TV and remote
myocardial areas (18 revascularizations and 1 MI). Event
rates were lower in survivors with remote versus TV area
events (9.8% vs. 14.3%, p  0.019), mostly due to the fact
that the rate of MIs was lower in remote than in TV areas
(Table 2). It is of note that 17 of 51 (33.3%) survivors with
TV events underwent repeat revascularization in addition to
an MI compared with only 4 of 38 (10.5%, p  0.01) of
those with remote events. Remote MI or revascularization
accounted for 46 of 124 (37.1%) of all late nonfatal events
(Fig. 2), which is similar in DES- and BMS-treated
patients (37.4% and 36.4%, respectively). Accordingly, there
were no significant differences between DES- and BMS-
treated patients in overall rates of death, MI, or revascular-
ization (all p  0.1, data not shown).
New late myocardial PDs. Compared to 6-month
SPECT findings, new 5-year PDs detected 5.0 0.25 years
after the initial SPECT studies were noted in 48 of 206
patients (23.3%). These defects were silent in 71%, be-
cause34 of 48 patients reported no anginal chest pain during
the intermittent history. Remote PDs accounted for 18 of
all 48 defects (37.5%) or 8.7% of all patients with SPECT
studies (Fig. 2) (72% were asymptomatic). Remote defects
were seen with similar frequency in patients with DES or
BMS (9.2% vs. 7.7%, p  0.8).
Late mortality. Survival status after 5 years was known in
812 of 826 (98.3%) of the total baseline population (lost to
follow-up: 2 patients early, 14 late) (Fig. 1). Overall, 115 of
812 (14.2%) patients died: 21 during the initial 6 months
and 94 thereafter. Thus, mortality rate per year was one-half
as high during months 7 to 60 (94 of 791 patients [21 had
died before, 14 lost] or 2.64% per year) as during months 0
to 6 (21 of 824 patients [2.54%] or 5.1% per year). It is of
note that cardiac causes of death after 6 months were
identified in only 43 of 94 patients (45.7%). Thus, late
TV Versus Remote Clinical Events During Months 7 to 60Table 2 TV Versus Remote Clinical Events During Months 7 to
Overall
(n  428)
O
T
Death n 43 (10) —
MI* n 36 (8.4) 27 (6
p Value
Revascularization† n 71 (16.6) 51 (1
p Value
Patients with any events‡ n 110 (25.7) 61 (1
p Value
Values are n (%). *TwoMIs could not be attributed to TV or remote areas (see Methods): 1 MI was a T
‡The first column includes death; the other columns do not include death. Some patients had 1 event.
BMS  bare-metal stent(s); DES  drug-eluting stent(s); MI  myocardial infarction; TV  target vessecardiac mortality per year was low, 1.21%, and comparable
to the noncardiac mortality rate (1.43%). There were no
significant differences in these mortality rates between
DES- and BMS-treated patients (1.3% vs. 1.0% for cardiac
and 1.5% vs. 1.2% for noncardiac mortality per year,
respectively; p  0.2 each).
Discussion
In this prospective, long-term outcome study of nonselected
patients with documented successful stent implantation, TV
events and/or new PDs remained more frequent than CAD
progression assessed by remote events and/or new PDs even
5 years after the intervention. However, remote events
accounted for almost 40% of all clinical events during these
5 years and, in addition, a similar rate of new PDs was
observed in patients without follow-up events. This was
similarly true for subgroups of patients randomized to DES
and BMS. Progression of CAD is likely even more impor-
tant than reported here because remote MIs and PDs may
not only occur in remote areas but also in TVs due to disease
progression proximal or distal to the stented lesion or in a
side branch (19). Together with the assumption that some
deaths also had a remote origin, up to one-half of all late
events and/or new PDs were due to CAD progression.
Progression occurred independently of stent type and man-
ifested as acute MI, need for repeat revascularization, new
PDs (which remained asymptomatic in 71%), or even death.
It is important to note that during this late period after
stenting, cardiac mortality rate was low (1.2% per year) and
similar to noncardiac mortality (1.4% per year).
Interesting additional observations were made. The rate
of late MIs was significantly higher in TV than remote areas
and this was true irrespective of stent type. In addition,
TV-related MIs were treated more often with revascular-
ization, mostly acute angioplasty, than remote MIs. It is
unknown whether this was due to the acute occlusion of a
previously widely open artery after stenting as seen in late
stent thrombosis, due to a lack of collateralization as
compared to a more progressive coronary occlusion in
nonpreviously treated lesions or to other unknown patient
factors. The possibility of underlying late stent thrombosis
(n  428) DES (n  284) BMS (n  144)
Remote TV Remote TV Remote
— — — — —
8 (1.9) 21 (7.4) 7 (2.5) 6 (4.2) 1 (0.125)
.002 0.011 0.125
38 (8.9) 36 (12.7) 27 (9.5) 15 (10.4) 11 (7.6)
.1 0.2 0.424
42 (9.8) 45 (15.8) 30 (10.6) 16 (11.1) 12 (8.3)
.019 0.037 0.424
emote area MI. †Eighteen revascularizations were done at the same time in TV and remote vessels.60
verall
V
.3)
0
1.9)
0
4.3)
0
V and rl.
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years after stent implantation (3,14) and has been noted in
this study in two-thirds of patients with MI, which is not
significantly more often in DES- versus BMS-treated pa-
tients. However, findings of a recent trial suggested that late
stent thrombosis may be less of a clinical issue with the use
of newer DES and current medical management, at least in
large coronary arteries (20).
The “natural history” of CAD in prior stent studies. The
“natural history” of CAD is a moving target because it
reflects disease progression, as well as the effects of drug and
revascularization therapies, secondary prevention, and life
style modification. The sum of these measures has been
associated with a significant decrease in overall mortality
(21). Revascularization by angioplasty and stenting contrib-
uted to this effect in patients with acute CAD (22,23), but
it did not reduce mortality in patients with chronic disease
(24,25). However, revascularization reduced ischemic symp-
toms consistently during the initial year of therapy (25).
Later on, this group difference disappeared due to many
medical patients needing revascularization for refractory
Figure 2 Incidence of TV and Remote Events and PDs 7 to 60
This figure shows the incidence of events in all 428 patients and the resulting proport
incidence of new perfusion defects (PDs) in 48 of 206 patients without events and thsymptoms and the fact that long-term outcome is deter-mined largely by disease progression as shown in a low-risk
clinical trial population after stenting (10).
Two prior studies addressing non-TV events in DES
versus BMS patients (11,12) had notable limitations. One
reported observations of pooled TAXUS trials with incom-
plete follow-up rates, difficulties in adjudication of late
events, and inclusion of patients with uncomplicated lesions
only as acknowledged limitations (11). The other study
based on the SIRIUS (Sirolimus-Eluting Stent in De Novo
Native Coronary Lesion) trial (12) also examined low-risk
patients with incomplete 5-year follow-up. The lack of
mortality data in 15% of patients and the likelihood that
spontaneous late MIs were missed were important limita-
tions here. In addition, all deaths were counted as TV as
well as non-TV events, making comparisons of remote
versus TV event rates even more difficult. In both studies,
outcomes were influenced by protocol-mandated follow-up
angiographies. Another recent study on the natural history
of CAD in a stent patient population showed that cardio-
vascular events during 3 years of follow-up were similarly
attributable to recurrence at culprit-lesion and non–culprit-
hs After Stenting
patients with remote and target-vessel (TV) events, respectively, as well as the
lting proportion of patients with remote and TV PDs. MI  myocardial infarction.Mont
ion of
e resulesion sites defined by baseline angiography (26). In contrast
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relevance of CAD progression after revascularization with
stent implantation. It is unique in that it included only
patients with successful, complete revascularization docu-
mented 6 months after stent implantation (important in
unselected multivessel CAD patients), had an almost com-
plete clinical 5-year follow-up (98%), and incorporated
serial SPECT studies performed in two-thirds of all pa-
tients without follow-up events, allowing for the first time
not only to evaluate late cardiovascular events but also
symptomatic and silent ischemia. Together, the prevalence
of clinically relevant CAD progression was much higher
than previously reported (11,12,26), about double that
observed based on clinical events alone, and this was true
independently of stent type used, in patients randomized to
DES versus BMS.
Role of serial scintigraphic testing. Myocardial perfusion
scintigraphy is a well-established method to detect serial
changes of myocardial perfusion after revascularization (27)
and after drug therapy (28). Findings of the present study,
the hitherto longest serial myocardial perfusion scinti-
graphic study covering a 5-year period, were consistent with
results of remote versus TV clinical events, reinforcing those
findings and demonstrating that CAD progression may
often manifest late as silent ischemia, if searched for.
Study limitations. The present study has several limitations.
About one-third of patients without events did not consent to
a second SPECT study. Deaths could not be attributed to any
coronary vessel (as in reference 26). Target-vessel events and
PDs could have occurred due to coronary obstructions remote
from the stent (discussed earlier) and the scintigraphic method
detects “clinically relevant” PDs but may underestimate CAD
progression. These facts limit a precise assessment of the
magnitude of CAD progression. This could only be achieved
with repeat coronary angiographies in all patients, an ethically
questionable endeavor using an invasive diagnostic test. How-
ever, based on the scintigraphic findings, the present study
suggests that the prevalence of CAD progression is at least
double that reported from clinical events alone. Then, in view
of relatively low numbers of patients, comparisons of subgroups
with DES versus BMS should only be done with great caution
in this trial, particularly relating to low-frequency events such
as stent thrombosis. Finally, these results relate to first-
generation DES, but because non-TV event rates did not differ
between stent types, results of CAD progression may hold true
also for future generations of stents.
Conclusions
The observation of BASKET-PRO that CAD progression
5 years after successful stent implantation is more prevalent
than previously assumed and independent of stent type has
important implications. The fact that close to 40% of all late
events and almost 40% of all new PDs in patients without
events were detected in areas remote from stents highlights
the importance of CAD progression and, thus, for long-term secondary prevention after revascularization. It stresses
the need to differentiate remote from stent-related TV
events and/or new PDs in long-term stent safety studies. In
addition, the high rate of silent CAD progression raises the
question whether or not all patients should undergo
ischemia-testing several years after stent implantation.
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